Skip to main content
. 2014 Sep 1;2(6):e00081. doi: 10.1002/prp2.81

Figure 1.

Figure 1

AZD5582 is a potent inhibitor of IAP proteins in CLL cells, but is not directly cytotoxic. (A) Primary CLL cells were incubated with 1 nmol/L AZD5582 for 48 h and then examined for levels of IAP proteins by Western blotting. β-actin was used as a loading control for densitometric analysis. The numbers under the lanes refer to the ratio of the respective IAP protein relative to β-actin, normalised to that of untreated cells in each sample. (B) Pooled quantitative analysis of the effect of AZD5582 on levels of XIAP, cIAP-1 and cIAP-2 in CLL cells as described in (A). In this and subsequent statistical analyses, a two-tailed t-test was performed to determine the statistical significance of the difference between the two groups of data (mean ± SD). (C) CLL cells were incubated with AZD5582 at the indicated concentrations for 24 and 48 h. Cell death was measured by flow cytometry following dual staining with FITC-conjugated annexin V and PI. The percentage of drug-induced cell death was calculated as: 100 × [(% cell death of drug-treated cells − % cell death of untreated cells)/(100 − % cell death of untreated cells)]. Each data point in the graph represents the mean ± SD of independent experiments using primary CLL cells from at least three patients.